Physician profile
Mark Chou
NPI 1578854543
$4,851.75
in general payments reported to CMS, 2019-2025
30 companies · $49.60 in 2025
The $49.60 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $519 · 2021: $1,115 · 2022: $494 · 2023: $188 · 2024: $798 · 2025: $49.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014 · Consulting Fee: $20.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.08 |
| Consulting Fee | $20.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,129.48 | 2019 | |
| Medtronic Vascular, INC. | $562.43 | 2019-2020 | |
| Boston Scientific Corporation | $473.89 | 2022-2024 | Ekosonic, Eluvia, Watchman Access System |
| Medtronic, INC. | $428.55 | 2021-2025 | Onyx Frontier, Linq II |
| Abbott Laboratories | $319.40 | 2021-2024 | Mitraclip |
| Janssen Pharmaceuticals, INC | $237.20 | 2020-2023 | Xarelto |
| Pfizer INC. | $229.44 | 2020-2024 | |
| Amgen INC. | $214.26 | 2019-2023 | Repatha |
| Novo Nordisk INC | $198.22 | 2019-2020 | |
| Philips North America LLC | $173.76 | 2020-2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $128.83 | 2022-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $112.59 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.72 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $83.95 | 2020-2021 | |
| Cardiovascular Systems INC. | $83.08 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.95 | 2021-2022 | |
| Angiodynamics, INC. | $51.64 | 2024 | Venacure 1470 Pro |
| Merck Sharp & Dohme LLC | $35.26 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $32.82 | 2022-2023 | |
| Cardiva Medical, INC. | $29.91 | 2021 | |
| Bardy Diagnostics, INC. | $25.14 | 2021 | |
| Amarin Pharma, INC. | $24.48 | 2020 | |
| Chiesi USA, INC. | $23.00 | 2021 | |
| Baxter Healthcare | $20.86 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $17.67 | 2020 | |
| Heartflow, INC. | $16.86 | 2024 | |
| Inspire Medical Systems, INC. | $16.61 | 2024 | Inspire |
| Tactile Systems Technology INC | $15.87 | 2022 | |
| Esperion Therapeutics, INC. | $15.13 | 2022 | |
| W. L. Gore & Associates, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.